Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10923652rdf:typepubmed:Citationlld:pubmed
pubmed-article:10923652lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0007776lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0022655lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0001613lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0017628lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0020452lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C0332261lld:lifeskim
pubmed-article:10923652lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:10923652pubmed:issue10lld:pubmed
pubmed-article:10923652pubmed:dateCreated2000-11-13lld:pubmed
pubmed-article:10923652pubmed:abstractTextWe investigated the contribution of ATP-sensitive potassium channels (K(ATP)) and calcium-activated potassium channels (Kca2+) to cortical spreading depression (CSD)-associated hyperemia using the rat closed cranial window model. The peak CBF response was enhanced by 12 +/- 5, 13 +/- 4, and 28 +/- 8% (p<0.01) of the control with 10(-6), 10(-5) and 10(-4) mol/l glibenclamide (glyb), a K(ATP) antagonist, respectively. We also calculated the area under the CBF curve to fully represent the extent of hyperemia during CSD. The area increased by 30 +/- 8 (p<0.05), 72 +/- 31 (p<0.05) and 88 +/- 20% (p<0.05) of the control with 10(-6), 10(-5) and 10(-4) mol/l glyb, respectively. However, charybdotoxin (CTX), a Kca2+ antagonist showed no effect. The effect of glyb was inhibited by pretreatment with 5 mg/kg indomethacin. We conclude that activation of K(ATP), perhaps associated with neurons, plays an inhibitory role in the CSD-associated hyperemia via an indomethacin-sensitive mechanism.lld:pubmed
pubmed-article:10923652pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:languageenglld:pubmed
pubmed-article:10923652pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:citationSubsetIMlld:pubmed
pubmed-article:10923652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10923652pubmed:statusMEDLINElld:pubmed
pubmed-article:10923652pubmed:monthJullld:pubmed
pubmed-article:10923652pubmed:issn0959-4965lld:pubmed
pubmed-article:10923652pubmed:authorpubmed-author:ShimizuKKlld:pubmed
pubmed-article:10923652pubmed:authorpubmed-author:BarkHHlld:pubmed
pubmed-article:10923652pubmed:authorpubmed-author:BusijaD WDWlld:pubmed
pubmed-article:10923652pubmed:issnTypePrintlld:pubmed
pubmed-article:10923652pubmed:day14lld:pubmed
pubmed-article:10923652pubmed:volume11lld:pubmed
pubmed-article:10923652pubmed:ownerNLMlld:pubmed
pubmed-article:10923652pubmed:authorsCompleteYlld:pubmed
pubmed-article:10923652pubmed:pagination2103-6lld:pubmed
pubmed-article:10923652pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:meshHeadingpubmed-meshheading:10923652...lld:pubmed
pubmed-article:10923652pubmed:year2000lld:pubmed
pubmed-article:10923652pubmed:articleTitleGlibenclamide enhances cortical spreading depression-associated hyperemia in the rat.lld:pubmed
pubmed-article:10923652pubmed:affiliationDepartment of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1083, USA.lld:pubmed
pubmed-article:10923652pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10923652pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10923652lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10923652lld:pubmed